Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8557MR)

This product GTTS-WQ8557MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8557MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14033MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ13273MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ13422MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ1871MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ3035MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ9318MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ5849MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ1098MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.